http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2255765-C2
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-03 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate | 2000-01-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2005-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5705346d0dc75b63be851e395ccb3010 |
| publicationDate | 2005-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2255765-C2 |
| titleOfInvention | Method for inhibiting cerebral tumors growth due to selected antagonists of integrins |
| abstract | FIELD: medicine, oncology. n SUBSTANCE: the present innovation deals with inhibiting the growth of host's cerebral tumors. It deals with introducing therapeutically efficient quantity of integrin α v antagonists being cyclo(Arg-Gly-Asp-D-Phe-[N-Me]-Val). The innovation enables to considerably inhibit cerebral oncogenesis in vivo, moreover, despite antiangiogenesis, due to induction of direct lethality of tumor cells. n EFFECT: higher efficiency of inhibition. n 9 dwg, 2 tbl |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9554988-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2672575-C2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2587041-C2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2705547-C1 |
| priorityDate | 2000-01-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 138.